<DOC>
	<DOC>NCT00113269</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal transplant recipients treated with tacrolimus, mycophenolate mofetil (MMF) and a rapid steroid withdrawal.</brief_summary>
	<brief_title>Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients</brief_title>
	<detailed_description>A 2 arm (1 Active, 1 Active Control) study is to compare the safety and efficacy of different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal transplant recipients treated with tacrolimus, MMF and a rapid steroid withdrawal.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Recipient of a primary or retransplanted deceased donor kidney or a primary or retransplanted nonhuman leukocyte antigen (HLA) living donor kidney (ie., HLA identical or 0 antigen mismatch deceased donor kidneys are allowed). Patient has previously received an organ transplant other than a kidney Patient receiving chronic steroid therapy at time of transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Treatment Effectiveness</keyword>
	<keyword>Treatment Efficacy</keyword>
	<keyword>Anti-rejection therapy</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Therapy, antirejection</keyword>
	<keyword>Renal Transplantation</keyword>
	<keyword>Transplantation, Kidney</keyword>
	<keyword>Transplantation, Renal</keyword>
	<keyword>Grafting, Kidney</keyword>
</DOC>